奈韦拉平（BI-RG-587）是一种HIV-1逆转录酶的非核苷类抑制剂，其Ki值为270 μM，可用于HIV/AIDS的相关研究。
|
英文别名 (English Synonym) |
Nevirapine |
|
中文名称 (Chinese Name) |
奈韦拉平 |
|
靶点 (Target) |
Reverse Transcriptase |
|
通路 (Pathway) |
Microbiology/Virology |
|
CAS号 (CAS NO.) |
129618-40-2 |
|
分子式 (Formula) |
C15H14N4O |
|
分子量 (Molecular Weight) |
266.3 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Dong JJ, Zhou Y, Liu YT, Zhang ZW, Zhou XJ, Wang HJ, Liao L. In vitro evaluation of the therapeutic potential of nevirapine in treatment of human thyroid anaplastic carcinoma. Mol Cell Endocrinol. 2013 May 6;370(1-2):113-8. doi: 10.1016/j.mce.2013.02.001. Epub 2013 Feb 24. PMID: 23462194.[2]Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999 Dec;27(12):1488-95. PMID: 10570031.
